Ratings for Neurocrine Biosciences NBIX were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 13 | 5 | 1 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 7 | 1 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $162.95, with a high estimate of $185.00 and a low estimate of $137.00. This current average has decreased by 4.65% from the previous average price target of $170.89.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $160.00 | $158.00 |
| Ami Fadia | Needham | Raises | Buy | $139.00 | $138.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $158.00 | $163.00 |
| Cory Kasimov | Evercore ISI Group | Lowers | Outperform | $185.00 | $190.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $168.00 | $185.00 |
| Ami Fadia | Needham | Announces | Buy | $138.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $137.00 | $138.00 |
| Ashwani Verma | UBS | Lowers | Buy | $137.00 | $154.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $184.00 | $183.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $150.00 | $185.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $185.00 | $185.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $185.00 | $185.00 |
| Yatin Suneja | Guggenheim | Lowers | Buy | $163.00 | $165.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $185.00 | $190.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $148.00 | $154.00 |
| Laura Chico | Wedbush | Lowers | Outperform | $147.00 | $157.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $163.00 | $172.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $185.00 | $190.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Buy | $179.00 | $184.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Discovering Neurocrine Biosciences: A Closer Look
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Neurocrine Biosciences: Delving into Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
